Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has made a significant investment in Neuro42 Inc., a US-based company specialising in advanced portable MRI systems. This move aims to transform neuroimaging and interventions with cutting-edge technology that brings advanced diagnostic and therapeutic solutions directly to patients’ bedsides.

Neuro42 is at the forefront of innovation with its portable MRI and robotic intervention technology. The company’s compact, user-friendly MRI scanner facilitates rapid diagnosis, while its robotic module is set to revolutionise procedures such as brain biopsies and ablations. Neuro42’s Diagnostic MRI platform has already received FDA 510(K) clearance for neuroimaging and is currently seeking regulatory approval for its interventional module.

Jay Kothari, Director of Zynext Ventures, underscored the strategic importance of this investment. He commented on the potential impact of Neuro42’s technology, stating that it “has the potential to reshape neuroimaging and interventions, enabling precise planning and execution of surgical procedures like shunts, biopsies, and laser therapy.” Kothari further noted that the investment would accelerate Neuro42’s progress and contribute to delivering groundbreaking solutions to patients.

Dr. Amit Vohra, Founder and CEO of Neuro42, expressed enthusiasm about the partnership, stating, “We are delighted to have Zynext as our strategic investor. The partnership will accelerate our mission in bringing our innovational neuroimaging and interventional products to global masses.”

The MRI imaging market in the United States was valued at approximately $1.8 billion in 2024, with neurology representing 23% of this market. According to the Centers for Disease Control and Prevention (CDC), there are 2.8 million cases of traumatic brain injury (TBI), 795,000 strokes, and 14,000 brain biopsies annually in the US alone. Neuro42 is strategically positioned to address these needs and drive significant advancements in the field.

Founded by a team of successful entrepreneurs and healthcare innovators, Neuro42 is a medical technology company focused on diagnostic imaging and image-guided interventions for neurological conditions. The company’s intraoperative MRI, AI, and robotic platform is designed to simplify MR imaging for screening, diagnosis, and intervention of neurological diseases. With over 50 patents, Neuro42’s platform promises to enhance both patient and physician experiences with its innovative and portable design.

  Centers for Disease Control and Prevention, Dr. Amit Vohra, FDA 510(K), Jay Kothari, MRI imaging, Neuro42 Inc., neuroimaging, robotic intervention, traumatic brain injury, Zydus Lifesciences, Zynext Ventures USA LLC